Please login to the form below
chemotherapy
This page shows the latest chemotherapy news and features for those working in and with pharma, biotech and healthcare.
AZ’s MYSTIC survival data is in – and it’s a bust
Trying to draw some good news from the data, AZ pointed to a 24% reduction in the risk of death for Imfinzi given on its own compared to chemotherapy, but prospects ... We remain confident in Imfinzi as the cornerstone of our IO programme and continue to
Latest news
-
Roche’s Genetech nabs speedy review for Tecentriq in first-line breast cancer
The company is seeking approval for first-line use of the drug in combination with Abraxane (chemotherapy) to treat unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in those
-
Soon-Shiong presents first data on cancer memory vaccine at SITC
Its ‘memory cancer vaccine’consists of a cocktail of off-the-shelf NK cells delivered alongside low-dose chemotherapy, cytokines, yeast- and adenovirus-delivered tumour antigens and PD-1/PD-L1
-
FDA clears first-line use for J&J’s myeloma drug Darzalex
ineligible for high-dose chemotherapy and autologous stem cell transplant (ASCT), a key front-line treatment strategy.
-
Roche and AbbVie prepare to move Venclexta into first-line CLL
the pairing as a first-line CLL regimen that spares patients from having to undergo chemotherapy. ... It was the first chemotherapy-free option for patients, having topped chlorambucil in trials, and is credited with re-shaping the CLL market.
-
Medical cannabis now available on prescription, for some
adults with vomiting or nausea caused by chemotherapy, and adults with muscle symptoms caused by multiple sclerosis. ... for instance in the areas of cancer pain and chemotherapy induced nausea and vomiting, ”she adds.
More from news
Approximately 6 fully matching, plus 835 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
Last year, the FDA approved Merck’s Keytruda (pembrolizumab) as a first-line agent alongside chemotherapy for metastatic NSCLC on data showing the chance of cancer progression was cut in half. ... Opdivo after standard treatment of early-stage lung
-
The threat of antimicrobial resistance
After all, so many of today’s life-saving healthcare advances, from cancer chemotherapy to heart surgery, rely on effective antibiotics being available to prevent infections in patients.
-
Taking a lean and careful approach
Chemotherapy and Pharmacology, which concluded its treatment regimen showed ‘encouraging clinical benefit’.
-
Reactivating drug research programmes
In the case of cancer treatment, such drugs could also help to limit the use of traditional chemotherapy, which can be costly and have undesirable side effects.
-
Deal Watch February 2017
As an ADC IMMU-132 contains SN-38, which is the active metabolite of the chemotherapy agent irinotecan, conjugated to an anti-TROP-2 antibody.
More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.
Latest appointments
-
Dr Sotirios Stergiopoulos leaves Shire for Ipsen
affairs strategies and a strong expertise in oncology drug development that includes chemotherapy, immunology drugs and targeted agents across various tumour indications.
-
BMS appoints oncology development head
Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions
-
AP Pharma overhauls senior management team
AP Pharma's lead product APF530 for the prevention of chemotherapy-induced nausea and vomiting.
-
AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales
AP Pharma appoints Dendreon’ s Jesse Hollingsworth to lead sales. Joins as company prepares to advance APF350 to treat side effects of chemotherapy. ... The appointment comes as AP Pharma prepares to advance its lead product APF350, which is intended
-
Bayer’s former oncology head Robert Rosen joins AP Pharma
Bayer’ s former oncology head Robert Rosen joins AP Pharma. Will lead launch of drug to prevent chemotherapy-induced nausea. ... In this role he will lead efforts at the US-based specialty pharma company to launch APF530 – AP Pharma's lead product
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Endometrial Cancer Treatment Market Analysis, Segments, Growth and Value Chain 2017-2027
Endometrial cancer can be treated by one or combination of chemotherapy, radiation therapy and hormone therapy. ... Most of the physicians recommend combination treatments as chemotherapy alone has traditionally been deem ineffective.
-
Leukemia Therapeutics Treatment Market Revenue, Opportunity, Segment and Key Trends 2015 - 2025
Etiology for leukemia includes artificial ionizing radiation, benzene and petrochemicals, alkylation chemotherapy agents, genetic predisposition and electromagnetic energy. ... Leukemia can be treated by blood transfusion, immunotherapy, bone marrow
-
Glioblastoma Treatment Drugs Market to Register Significant Growth Globally During 2026
Treating such tumors is a challenge which forces the researchers to look for diagnosis and newer chemotherapy drugs. ... More treatments are coming forward which can be used alone or in combination with radiotherapy and chemotherapy, but there are
-
CASE STUDY: Creation of Global Value Dossiers for a US-based Global Pharmaceutical Company
Febrile Neutropenia (FN) during adjuvant chemotherapy is associated with significant morbidity, mortality risk, and incremental costs. ... The client wanted a vendor to develop content for a Global Value Dossier (GVD) about the burden of febrile
-
Forecasting in Dynamic Oncology Markets
future. Industry commentators believe immuno-oncology to be the third major breakthrough in cancer treatment, following the early days of chemotherapy and the targeted treatments that followed on from them. ... Only by combining with traditional
More from PMHub
Approximately 0 fully matching, plus 15 partially matching documents found.
Featured jobs
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Director, Market Access / HEOR - North-West
-
Negotiable
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Medical Writers
-
Competitive Salary and Benefits
- Senior Account Executive, London, Medical Communications
-
Excellent package
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
-
Account Director
-
£48, 000 - £60, 000
- Account Manager, Healthcare Public Affairs
-
£32, 000 – £40, 000 benefits
-
Associate Medical Director
-
Highly Competitive
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
Associate Director
-
£75, 000-90, 000
-
New Business Director - PR
-
Competitive Salary and benefits
-
Account Manager / Account Director
-
Competative
Subscribe to our email news alerts
- Oral Appliances lead Sleep Apnea Devices Market Growth, Shows Recent Analysis
- Animal Healthcare Market is poised to cross USD 36 billion by 2024
- Fishawack launches new website and introduces new structure for growth
- OUTiCO win Best in UK Pharmaceutical Outsourcing award
- Orphan drugs from Biogen and Amicus win UK Prix Galien
- AZ’s MYSTIC survival data is in – and it’s a bust
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- OUTiCO win Best in UK Pharmaceutical Outsourcing award
- The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
- Artificial Intelligence in Healthcare
- Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
Quick links
Infographics
